Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia

    Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia

    FromThe Lancet Haematology in conversation with

    Start listeningView podcast show

    Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia

    FromThe Lancet Haematology in conversation with

    ratings:
    Length:
    12 minutes
    Released:
    Nov 25, 2021
    Format:
    Podcast episode

    Description

    Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext 
    Released:
    Nov 25, 2021
    Format:
    Podcast episode

    Titles in the series (43)

    Lan-Lan Smith, Editor-in-Chief of The Lancet Haematology, and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.